What Is Retatrutide

What Is Retatrutide?

Retatrutide (also known by its research code LY3437943) is an investigational weight loss medication developed by Eli Lilly and Company. It belongs to the same broad family as semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound), but with a critical difference: retatrutide targets three hormone receptors instead of one or two.

Specifically, retatrutide is a triple-hormone-receptor agonist that simultaneously activates:

• GLP-1 receptors (glucagon-like peptide-1) — the same target as semaglutide
• GIP receptors (glucose-dependent insulinotropic polypeptide) — the additional target that tirzepatide added
• Glucagon receptors — the entirely new, third pathway that no approved obesity drug currently targets

The drug is administered as a once-weekly subcutaneous injection, similar to Wegovy and Mounjaro. It is a 39-amino-acid peptide linked to a fatty acid chain that gives it a half-life of approximately six days, allowing weekly dosing.

In clinical trials, retatrutide has produced the largest average weight loss ever recorded for any obesity medication — up to 28.7% of body weight over 68 weeks. To put that in perspective, that is an average loss of roughly 5 stone (71 lbs / 32 kg) for a typical trial participant.

But retatrutide is not just about the number on the scale. Its unique glucagon receptor activity gives it significant effects on liver fat, energy expenditure, and metabolic health that go beyond what current GLP-1 drugs can achieve. This is why researchers and clinicians consider it a potential step-change in obesity treatment — not just an incremental improvement.

How Retatrutide Works: The Triple Agonist Mechanism

To understand why retatrutide is generating so much attention, you need to understand what each of its three receptor targets does — and why combining all three in a single molecule is such a significant advance.

GLP-1: The Appetite Suppressor

GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after eating. It tells your brain you are full, slows the rate at which food leaves your stomach (gastric emptying), and stimulates insulin release to help process blood sugar.

This is the mechanism behind semaglutide (Wegovy/Ozempic). By mimicking GLP-1, these drugs reduce appetite, decrease food intake, and improve blood sugar control. The GLP-1 pathway is well-established and has been the backbone of modern obesity pharmacotherapy since 2021.

Retatrutide activates GLP-1 receptors, but with relatively lower potency compared to dedicated GLP-1 agonists. The reduced GLP-1 activity may actually be beneficial — it could mean fewer gastrointestinal side effects while the other two pathways compensate for weight loss efficacy.

GIP: The Metabolic Amplifier

GIP (glucose-dependent insulinotropic polypeptide) is another gut hormone, sometimes called the "forgotten incretin." For decades it received less attention than GLP-1, but tirzepatide (Mounjaro) proved that adding GIP activation to GLP-1 produced significantly greater weight loss than GLP-1 alone.

GIP enhances insulin secretion in a glucose-dependent manner (meaning it helps when blood sugar is elevated but does not cause dangerous lows), plays a role in fat metabolism, and appears to work synergistically with GLP-1 to amplify satiety and metabolic improvements.

Retatrutide is actually most potent at the GIP receptor compared to its activity at the other two. This strong GIP activation likely contributes to its exceptional glucose-lowering effects in people with type 2 diabetes.

Glucagon: The Breakthrough Third Pathway

This is the part that most articles about retatrutide get wrong — or skip entirely. The glucagon receptor is the truly novel element, and it is the reason retatrutide's results exceed those of every other obesity drug.

Glucagon is a hormone produced by the alpha cells of the pancreas. Most people associate it with raising blood sugar (it is the counter-regulatory hormone to insulin), which is why it seems counterintuitive to activate it in a drug designed to help with diabetes and obesity.

But glucagon does far more than raise blood sugar. When you activate glucagon receptors, you trigger a cascade of metabolic effects:

• Increased energy expenditure: Glucagon stimulates thermogenesis — your body burns more calories at rest. Unlike GLP-1 drugs that primarily reduce calorie intake, glucagon activation increases calorie output. This "burn more" effect on top of the "eat less" effect of GLP-1 is why retatrutide produces such dramatic results.
• Fat breakdown (lipolysis): Glucagon directly promotes the breakdown of stored fat, particularly in the liver and visceral fat deposits. It activates the protein kinase A signalling pathway, which triggers lipid mobilisation even when the body is at rest.
• Liver fat reduction: This is arguably glucagon's most significant contribution. Glucagon stimulates hepatic fatty acid oxidation (the liver burns fat for fuel) and simultaneously reduces hepatic lipogenesis (the liver makes less new fat). This dual action explains retatrutide's extraordinary results in fatty liver disease, which we cover in detail below.
• Beta-hydroxybutyrate production: In clinical trials, retatrutide doses of 4 mg and above increased beta-hydroxybutyrate levels two to threefold. This biomarker of fatty acid oxidation confirms that the glucagon pathway is actively burning fat.

The reason no approved drug has targeted the glucagon receptor until now is the blood sugar concern — glucagon raises blood glucose, which is exactly what you do not want in people with type 2 diabetes. Retatrutide solves this elegantly: the GLP-1 and GIP components counterbalance the glucose-raising effect of glucagon with their own insulin-stimulating properties. The three receptors work together, each offsetting the other's limitations.

Think of it this way: semaglutide reduces your appetite (one lever). Tirzepatide reduces your appetite more effectively (two levers). Retatrutide reduces your appetite and increases how many calories your body burns and directly breaks down liver and visceral fat (three levers). That is why researchers have called it a potential "home run" for obesity treatment.

Clinical Trial Results

Phase 2: The Obesity Trial (Jastreboff et al., NEJM 2023)

The landmark Phase 2 trial that put retatrutide on the map was published by Jastreboff and colleagues in the New England Journal of Medicine in June 2023. This randomised, double-blind, placebo-controlled trial enrolled 338 adults with obesity (BMI of 30 or above) or overweight (BMI 27–30 with at least one weight-related condition).

Participants were assigned to weekly subcutaneous injections of retatrutide at 1 mg, 4 mg, 8 mg, or 12 mg — or placebo — for 48 weeks. Higher doses began with a lower starting dose (2 mg or 4 mg) with gradual escalation over 12 weeks to improve tolerability.

The 24.2% weight loss at the 12 mg dose was unprecedented at the time of publication — exceeding the results seen with semaglutide 2.4 mg (~15% at 68 weeks in the STEP trials) and tirzepatide 15 mg (~22.5% at 72 weeks in SURMOUNT-1). Importantly, the weight loss curves at 48 weeks had not yet plateaued, suggesting even greater losses would be seen over longer treatment periods.

Phase 2: The Type 2 Diabetes Trial (Rosenstock et al., The Lancet 2023)

A parallel Phase 2 trial, published by Rosenstock and colleagues in The Lancet, evaluated retatrutide in adults with type 2 diabetes. This study tested a wider range of doses (0.5 mg to 12 mg) over 36 weeks, with dulaglutide 1.5 mg (Trulicity) as an active comparator.

Key findings in the type 2 diabetes population:

• HbA1c reduction: Retatrutide lowered HbA1c by 1.3% to 2.0% across the 4–12 mg doses, compared to no change with placebo and a 1.4% reduction with dulaglutide
• Target achievement: Up to 82% of participants on retatrutide achieved an HbA1c below 6.5% — often considered the threshold for remission of type 2 diabetes
• Weight loss: 16.9% body weight reduction at the 12 mg dose over 36 weeks (lower than the obesity trial because diabetes typically blunts the weight loss response to incretin-based therapies)
• Retatrutide significantly outperformed dulaglutide at the 8 mg and 12 mg doses for both HbA1c reduction and weight loss

Phase 3: The TRIUMPH Programme

Based on the Phase 2 results, Eli Lilly launched the TRIUMPH Phase 3 clinical development programme in 2023 — one of the largest obesity drug trial programmes ever undertaken. TRIUMPH encompasses multiple large-scale trials evaluating retatrutide across different conditions:

TRIUMPH-4 Results (December 2025) — The First Phase 3 Win

The first Phase 3 readout from the TRIUMPH programme came in December 2025, and the results were remarkable. TRIUMPH-4 was a global, randomised, double-blind trial in adults with obesity or overweight and moderate-to-severe knee osteoarthritis.

Participants received either retatrutide (9 mg or 12 mg) or placebo for 68 weeks. The co-primary endpoints were weight loss and improvement in knee osteoarthritis pain (measured by the WOMAC pain scale).

The 28.7% weight loss at the 12 mg dose is the highest ever recorded in a Phase 3 obesity drug trial. In addition to weight loss, retatrutide significantly reduced cardiovascular risk markers including non-HDL cholesterol, triglycerides, high-sensitivity C-reactive protein (hsCRP), and systolic blood pressure.

Analysts project that the longer TRIUMPH-1 trial (80 weeks) could show weight loss exceeding 30% when those results are released in 2026.

Retatrutide vs Semaglutide vs Tirzepatide

The weight loss medication landscape has evolved rapidly. Here is how retatrutide compares to the two most widely used GLP-1-based drugs currently available in the UK.

The comparison reveals a clear evolution: from one receptor (semaglutide), to two (tirzepatide), to three (retatrutide), each generation delivering incrementally greater weight loss and metabolic improvement. The glucagon pathway adds a dimension that neither of the existing drugs can match — particularly in liver fat reduction and energy expenditure.

However, it is important to note that retatrutide has not been tested in a head-to-head trial against semaglutide or tirzepatide. The comparisons above are based on results from separate trials with different populations, which means they should be interpreted with caution. Differences in trial design, participant demographics, and endpoint timing make direct comparison imperfect.

Retatrutide and Fatty Liver Disease (MASH)

If there is one area where retatrutide truly distinguishes itself from every other weight loss medication, it is liver fat reduction. The data here is extraordinary — and it is barely covered by most competitor articles about the drug.

What Is MASH?

Metabolic dysfunction-associated steatohepatitis (MASH) — previously known as NASH (non-alcoholic steatohepatitis) — is a progressive liver condition where excess fat accumulation in the liver causes inflammation and cell damage. It affects an estimated 3–5% of the global population and is the leading cause of liver transplantation in many countries. The milder form, MASLD (metabolic dysfunction-associated steatotic liver disease, formerly NAFLD), involves fat accumulation without significant inflammation and affects roughly 25% of adults worldwide.

Until recently, there were almost no effective pharmacological treatments for fatty liver disease. Weight loss of 7–10% through diet and exercise can improve the condition, but most people struggle to achieve and maintain this level of loss. This is where retatrutide's glucagon pathway becomes particularly relevant.

The Phase 2a MASLD/MASH Results

A Phase 2a sub-study, published in Nature Medicine in 2024, specifically evaluated retatrutide's effects on liver fat in participants with obesity and elevated liver fat content (above 10% at baseline). The results, measured by MRI-proton density fat fraction (MRI-PDFF), were striking:

Let those numbers sink in. At the 12 mg dose, 93% of participants who started with clinically significant fatty liver achieved normal liver fat levels by 48 weeks. The mean relative reduction was 86%. No other drug — not semaglutide, not tirzepatide, not resmetirom (the only FDA-approved MASH drug) — has come close to these results.

Why Glucagon Matters for Liver Fat

The reason retatrutide is so effective for fatty liver comes back to the glucagon receptor. Glucagon directly stimulates the liver to burn stored fat through a process called hepatic fatty acid oxidation, while simultaneously suppressing the liver's ability to create new fat (hepatic de novo lipogenesis). This two-pronged attack on liver fat — burn more, make less — is unique to retatrutide among the GLP-1 drug class.

The clinical confirmation of this mechanism came through beta-hydroxybutyrate measurements. This biomarker of fatty acid oxidation increased two to threefold in participants on retatrutide doses of 4 mg and above, with the largest increases occurring by week 24 — exactly when most of the liver fat reduction had already occurred.

If you are concerned about liver function or have been told your GGT levels are elevated, this is particularly relevant. Fatty liver is often a silent condition that shows up first on blood tests as elevated liver enzymes (ALT, AST, GGT) before any symptoms appear. Retatrutide's ability to resolve fatty liver could eventually represent one of the most important clinical applications of the drug — perhaps even more significant than weight loss alone.

A dedicated MASLD Phase 3 trial within the TRIUMPH programme is expected to report results in 2026, which will confirm whether these extraordinary Phase 2 findings hold up in a larger population.

Side Effects of Retatrutide

Like all GLP-1-based medications, retatrutide causes side effects — primarily gastrointestinal. However, there is one side effect that is relatively unique to retatrutide and which most competitor content fails to mention: dysesthesia.

Gastrointestinal Side Effects

Gastrointestinal (GI) adverse events were the most commonly reported side effects across all retatrutide trials. They were dose-dependent, more frequent during dose escalation, and generally mild to moderate in severity. Most subsided as participants continued treatment.

In the Phase 2 obesity trial:

• Overall adverse events occurred in 73–94% of retatrutide groups (vs 70% placebo), with the highest rates at 8 mg and 12 mg
• The most common GI side effects were nausea, diarrhoea, vomiting, and constipation
• Rates at lower doses (1–4 mg) were comparable to other GLP-1 drugs; at 8–12 mg, GI rates were higher
• Using a lower starting dose with gradual escalation significantly reduced the frequency and severity of GI events
• Adverse events leading to discontinuation occurred in 6–16% of retatrutide participants vs 0% for placebo
• Serious adverse events occurred in 0–6% of retatrutide groups vs 4% placebo

Dysesthesia: The Side Effect Nobody Talks About

Dysesthesia is an abnormal, often unpleasant sensation affecting touch perception. It can manifest as:

• Tingling or "pins and needles" across the skin
• Burning sensations without apparent cause
• Unusual sensitivity to pressure, heat, or touch
• Skin tenderness
• Numbness in certain areas

In the TRIUMPH-4 Phase 3 trial, dysesthesia was reported in:

• 0.7% of the placebo group
• 8.8% of the 9 mg group
• 20.9% of the 12 mg group

That is a striking number — roughly 1 in 5 people on the highest dose experienced some form of abnormal skin sensation. However, the events were classified as generally mild and rarely led to treatment discontinuation.

Dysesthesia was first flagged as a potential class effect of highly potent GLP-1-based therapies in 2023, when it was observed with both high-dose oral semaglutide and retatrutide. The mechanism is not fully understood, but it may relate to rapid metabolic changes, neural effects of the medications, or a combination of factors. Research into this side effect is ongoing.

If you are tracking your health with blood tests, monitoring nerve function-related markers and reporting any unusual skin sensations to your doctor is especially important when starting any incretin-based medication.

Heart Rate Changes

Like other GLP-1 agonists, retatrutide causes a dose-dependent increase in heart rate, which was observed during the first 24 weeks of treatment before declining. This is consistent with the GLP-1 drug class and is generally not considered clinically significant in otherwise healthy individuals, but it should be monitored in people with pre-existing cardiovascular conditions.

When Will Retatrutide Be Available in the UK?

This is the question everyone in the UK wants answered. Unfortunately, the honest answer is: not soon. Here is the most realistic timeline based on what we know as of February 2026.

The Regulatory Pathway

Key Caveats

• Eli Lilly has not announced an official filing date. All timelines are estimates based on trial completion schedules and typical regulatory review periods.
• Delays are possible. If additional safety signals emerge in the remaining Phase 3 trials (particularly around dysesthesia), the FDA or MHRA may request additional data, extending the timeline.
• Private availability could come earlier. Once the MHRA grants a marketing authorisation, private clinics and online prescribers can offer retatrutide before NICE completes its cost-effectiveness appraisal. This happened with tirzepatide, where private prescriptions were available months before NHS access.
• Supply constraints are likely. Eli Lilly experienced significant manufacturing challenges with tirzepatide's launch. Given the anticipated demand for retatrutide, supply shortages in the early months are probable.

Bottom line: If you are in the UK and interested in retatrutide, the most realistic expectation is that it will be available through private prescribers in late 2027 or 2028, with NHS access following in 2028 or 2029. In the meantime, semaglutide and tirzepatide remain the available options, and blood testing remains the best way to monitor your metabolic health regardless of which medication you use.

Blood Tests for Retatrutide Monitoring

When retatrutide eventually becomes available, comprehensive blood testing will be essential before starting treatment, during dose escalation, and at regular intervals throughout therapy. Based on the clinical trial data and the drug's triple mechanism of action, here are the key biomarker panels that doctors will need to monitor.

1. Blood Sugar and Metabolic Markers

Retatrutide's triple agonist mechanism profoundly affects glucose metabolism. The GLP-1 and GIP components stimulate insulin, while the glucagon component raises blood glucose — meaning the balance of these forces needs monitoring.

• HbA1c — The gold standard for 3-month average blood sugar. Retatrutide reduced HbA1c by up to 2.0% in the Phase 2 diabetes trial. Essential for tracking glycaemic improvement and detecting potential hypoglycaemia risk.
• Fasting glucose — Acute snapshot of blood sugar control.
• Fasting insulin — Assesses insulin resistance. Retatrutide should improve this marker over time.

2. Liver Function Panel

Given retatrutide's dramatic effects on liver fat, liver function tests are arguably the most important monitoring panel for this drug.

• ALT (alanine transaminase) — The primary marker for liver cell damage. Should decrease as liver fat resolves.
• AST (aspartate transaminase) — Another liver enzyme; the ALT/AST ratio helps distinguish fatty liver from other causes.
• GGT (gamma-glutamyl transferase) — Sensitive to fatty liver disease and biliary damage. Often the first liver enzyme to become elevated in MASLD/MASH.
• Albumin — Marker of liver synthetic function. Important in advanced disease.
• Bilirubin — To rule out biliary obstruction or more serious liver pathology.

3. Kidney Function

Significant weight loss, reduced food intake, and potential dehydration from GI side effects all place demands on kidney function. Monitoring is particularly important during dose escalation when GI symptoms peak.

• Creatinine and eGFR — Standard kidney function assessment. Changes may indicate dehydration or medication-related effects.
• Urea (BUN) — Rises with dehydration, which is common during the early weeks of GLP-1 therapy.

4. Thyroid Function

All GLP-1 receptor agonists carry a precautionary warning about thyroid C-cell tumours (observed in rodent studies, not confirmed in humans). Thyroid monitoring is standard practice for anyone on these medications.

• TSH — Screening for thyroid dysfunction. Weight loss can also affect thyroid hormone levels.
• Free T4 — Particularly important if already on levothyroxine (dose adjustments may be needed as weight decreases).

5. Lipid Panel

Retatrutide significantly improved lipid profiles in clinical trials, including reductions in non-HDL cholesterol, triglycerides, and hsCRP. Regular lipid monitoring tracks this improvement.

• Total cholesterol, LDL, HDL — Full lipid profile.
• Triglycerides and triglyceride-to-HDL ratio — Particularly sensitive to metabolic improvement and fatty liver resolution.

6. Pancreatic Enzymes

GLP-1 drugs carry a theoretical risk of pancreatitis. While retatrutide's clinical trials have not shown a significant signal, monitoring pancreatic enzymes is a sensible precaution, particularly during the first year of treatment.

• Lipase — The most sensitive marker for pancreatic inflammation.
• Amylase — A supporting marker for pancreatitis screening.

7. Nutritional Markers

Significant and rapid weight loss through reduced food intake can deplete essential vitamins and minerals. This is often overlooked in medication monitoring but is critical for long-term health.

• Vitamin B12 — Commonly depleted with reduced food intake.
• Folate — Important for methylation and red blood cell production.
• Vitamin D — Often already low in the UK population; weight loss medication can worsen deficiency.
• Iron studies (ferritin, iron, TIBC) — Anaemia risk increases with reduced dietary intake.

Recommended Testing Schedule

Frequently Asked Questions

References and Sources

1. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple–hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526. NEJM
2. Rosenstock J, Frias JP, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet. 2023;402(10401):529-544. PubMed
3. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024. Nature Medicine
4. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. December 2025. Eli Lilly Press Release
5. Giblin MJ, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes, Obesity and Metabolism. 2026. Wiley Online Library
6. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247. PMC